Ondansetron Placebo

DRUG5 trials

Conditions

Chemotherapy-Induced Nausea and Vomiting (CINV)Chemotherapy-induced Nausea and VomitingNauseaPostoperative Nausea and Vomiting (PONV)SchizophreniaVomiting

Phase 1

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

TerminatedNCT02614586

TakedaSchizophrenia

Start: 2015-12-31End: 2016-04-30Updated: 2017-05-01

Phase 2

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery

CompletedNCT04557189

TakedaPostoperative Nausea and Vomiting (PONV)

Start: 2020-10-20End: 2022-03-21Updated: 2023-04-21

Phase 3

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

CompletedNCT01594749

Merck Sharp & Dohme LLCChemotherapy-Induced Nausea and Vomiting (CINV)

Start: 2012-09-24End: 2014-11-03Updated: 2018-09-04

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

CompletedNCT02106494

Heron TherapeuticsChemotherapy-induced Nausea and Vomiting

Start: 2014-03-01End: 2015-05-01Updated: 2026-03-02

Phase 4

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

CompletedNCT01636947

Merck Sharp & Dohme LLCNausea, Vomiting

Start: 2012-12-12End: 2014-08-04Updated: 2018-09-25

BMC Cancer2020-09-259 citations

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.

2018-05-288 citations

Abstract P6-11-11: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer receiving moderately emetogenic chemotherapy regimens

Cancer Research2018-02-152 citations

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based therapies.

Journal of Clinical Oncology2017-05-20

Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.

2016-11-0811 citations

Effect of APF530 on health-related quality of life (QOL) and other chemotherapy-induced nausea and vomiting (CINV) end points: Phase III MAGIC trial.

Journal of Clinical Oncology2016-05-203 citations

Phase III MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (Fos) + dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender.

Journal of Clinical Oncology2016-05-201 citations

APF530 (Granisetron Injection Extended-Release) in a Three-Drug Regimen for Delayed CINV in Highly Emetogenic Chemotherapy

Future Oncology2016-03-2122 citations

Abstract P1-10-07: Phase 3 comparison of APF530 versus ondansetron, each in a guideline-recommended 3-drug regimen for prevention of chemotherapy-induced nausea and vomiting due to anthracycline + cyclophosphamide (AC)–based highly emetogenic chemotherapy (HEC) regimens: A post hoc subgroup analysis of the MAGIC trial

Cancer Research2016-02-152 citations

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial.

2015-10-0855 citations

Phase III study of APF530 versus ondansetron with a neurokinin 1 antagonist + corticosteroid in preventing highly emetogenic chemotherapy-induced nausea and vomiting: MAGIC trial.

Journal of Clinical Oncology2015-10-01

A phase III, randomized, double-blind study of single-dose intravenous fosaprepitant in preventing chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.

Journal of Clinical Oncology2015-05-203 citations

Phase III design for a trial of single-dose fosaprepitant (FA) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC).

Journal of Clinical Oncology2014-05-20